This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Transparency, Aggregate Spend & HCP Engagement 2024
Delivered as a Hybrid Event August 13-15, 2024
The Ritz-Carlton, Tysons CornerMcLean, VA

Valerie Burkholder
Manager at Baker Tilly US, LLP
Speaker

Profile

Valerie is an experienced team member on the life sciences consulting team. She has over 30 years’ experience in the life sciences, including a 28-year career at a mid-sized pharmaceutical company. She has executed fair market value strategy, compliance monitoring, and transparency reporting services for a number of healthcare clients in the pharmaceutical and medical device industry. She is a subject matter expert in the Fair Market Value space and has presented at national conferences on the subject.

Specific experience:

  • Acted in leadership position for Fair Market Value (FMV) service offering with activities including, but not limited to, creating internal work documents and processes, developing and qualifying potential client leads, conducting internal team trainings, leading large global FMV engagements (> $150k+), etc.
  • Determined global Fair Market Value (FMV) rate structures for Healthcare Professionals (HCPs) and certain non-HCPs performing consulting services (advisory boards, speaker programs, training, ad hoc) for pharmaceutical manufacturers
  • Conducted compliance monitoring of speaker programs and field sales interactions for large pharmaceutical company
  • Provided global transparency reporting services for multiple pharmaceutical and medical device companies including data collection and remediation, formatting into required templates, uploading and correcting submissions, and managing disputes.
  • Evaluated “current state” processes, procedures, and documentation to support manufacturer in its efforts to improve adherence to internal policies and build efficiencies into FMV determination of investigator-initiated agreements.

Agenda Sessions

  • Key Considerations in Determining FMV

    1:00pm